AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +75

Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead

AI-generated analysis

📈 AbbVie reported Q2 revenue of nearly $17 billion, representing a 10.2% increase compared to the prior year.

💊 Skyrizi sales reached $5.5 billion in the quarter, marking a significant 24% growth rate.

💊 Rinvoq sales exceeded $2.5 billion, achieving a robust 23.7% increase during the same period.

📈 Management raised full-year EPS guidance to a range of $13.87 to $14.07.

🤝 AbbVie signed a $10.9 billion deal with Apogee Therapeutics to expand its portfolio.

💉 The company is preparing to launch Skyrizi as a subcutaneous injection for Crohn's disease.

💰 AbbVie increased its annualized dividend to $6.92, up from $6.56 in the previous year.

📈 Piper Sandler raised its price target on AbbVie shares to $303 with an Overweight rating.

🎯 Analysts project a potential share price of $325 by 2027 if growth targets are met.

📉 The current forward P/E multiple is approximately 18x, below the implied 23x at the $325 target.

Bullish Signals
  • AbbVie reported Q2 revenue of nearly $17 billion, a 10.2% increase year-over-year.
  • Skyrizi sales reached $5.5 billion in the quarter, growing by 24%.
  • Rinvoq sales surpassed $2.5 billion, achieving a 23.7% increase.
  • Management raised full-year EPS guidance to a range of $13.87 to $14.07.
  • Piper Sandler raised its price target on AbbVie shares to $303 with an Overweight rating.
  • The company signed a $10.9 billion deal with Apogee Therapeutics.
  • AbbVie increased its annualized dividend to $6.92, up from $6.56 in the prior year.
Full Analysis
AbbVie (NYSE:ABBV) has demonstrated strong financial performance in the second quarter, reporting revenue of nearly $17 billion, a 10.2% increase year-over-year. The company's growth is primarily driven by its blockbuster biologic drugs, with Skyrizi generating $5.5 billion and Rinvoq surpassing $2.5 billion in sales during the period. Management has raised full-year earnings per share (EPS) guidance to a range of $13.87 to $14.07, reflecting confidence in the company's pipeline and execution capabilities. Analyst Piper Sandler recently increased its price target on AbbVie shares to $303 while maintaining an Overweight rating, citing the firm's robust long-term outlook. Strategic initiatives are poised to further accelerate growth, including a $10.9 billion agreement with Apogee Therapeutics and the upcoming launch of Skyrizi as a subcutaneous formulation for Crohn's disease. The company continues to prioritize shareholder returns, having raised its annualized dividend to $6.92 from $6.56 in the prior year. Looking ahead to 2027, AbbVie aims to achieve a share price of $325, which would imply a forward P/E multiple of approximately 23x. This target relies on sustained beat streaks, successful pipeline delivery, and favorable macroeconomic conditions to support the valuation expansion required to reach this level.